Categorynews

Rheumatoid Arthritis (RA) Therapy Area Report, 2022 – Uncover Key Unmet Needs of Patients, Hot Topics of Conversation Amongst Physicians, and Assess Pharma Company Online Activity – ResearchAndMarkets.com

February 18, 2022 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Rheumatoid Arthritis (RA) Therapy Area Report” report has been added to ResearchAndMarkets.com’s offering.

This latest report offers fresh insights into the Rheumatoid Arthritis (RA) online space, from the perspective of multiple stakeholders, as well as evaluating key companies’ social media activity.

The report, which is based on both machine and human-led analysis, uncovers the key unmet needs of patients, hot topics of conversation amongst physicians and assess pharma company online activity. Insights from this report can help pharma companies identify potential opportunities to understand how to best engage with and support keys stakeholders.

Key Topics Covered

1. Introduction

  • Executive Summary, Methodology and Background

2. RA Social Media Landscape Overview

  • Social Media Conversation Architecture

3. The Patient Voice

  • Patient Audiences in RA
  • Key Topics of Patient Conversation
  • Disease Experiences:
  • Diagnosis
  • Unmet Needs in Young Adult / Pregnant Women
  • Mental Health Impact
  • COVID-19 and RA
  • Treatment Experiences:
  • Brand Discussion
  • Treatment Switching
  • Safety Discussions
  • JAKi Safety Discussion and Key Questions Asked
  • Mode of Administration
  • Remission Discussion
  • Summary and Opportunities from the Patient Conversation

4. Clinical Conversations

  • Physician Online Audiences
  • Key Topics of Physician Conversation
  • Physician Views on JAKi Safety
  • Key Conference SoV
  • EULAR 2021 Discussions
  • ACR 2021 Discussions
  • Top Digital Opinion Leaders in RA
  • Summary and Opportunities from the Physician Conversation

5. Competitive Intelligence

  • Summary of Key Company Online Performance
  • Key Company Social Media Presence
  • Company Social Media Activity Overview:
  • UCB
  • Galapagos
  • BMS
  • Amgen
  • Pfizer
  • Sanofi
  • AbbVie
  • Genentech
  • Janssen
  • Eli Lilly
  • Summary and Opportunities from the Pharma Conversation

Companies Mentioned

  • AbbVie
  • Abivax
  • Alvotech
  • Amgen
  • Amgen
  • Archigen Biotech Limited
  • Biogen
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Coherus Biosciences
  • Dr. Reddy’s Laboratories
  • Eli Lilly
  • FujiFilm
  • Galapagos
  • Genentech
  • GSK
  • Janssen
  • Johnson & Johnson
  • Lupin
  • Merck
  • Mylan
  • Nichi-Iko Pharmaceutical
  • Pfizer
  • R-Pharm
  • Regeneron
  • Roche
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Teva
  • UCB

For more information about this report visit https://www.researchandmarkets.com/r/kzjsa4

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900